other
confidence high
sentiment neutral
materiality 0.25
Alaunos directors convert $139K deferred fees to equity: shares + options
Alaunos Therapeutics, Inc.
- Total deferred board service fees of $139,000 from Q3 2024 through Q1 2025 converted to equity.
- Issued 38,269 common shares with aggregate fair value of $111,750.
- Granted 10,904 fully vested stock options at $2.92 exercise price, aggregate fair value $27,250.
- Board elected equity over cash under Non-Employee Directors Compensation Policy.